Editor's note: This article is written by employees of DaVita Clinical Research.
For the first time in 15 years, the United States Renal Data System (USRDS) Report this year failed to include comparisons of mortality and hospitalization rates of the large for-profit dialysis providers (DaVita and Fresenius) and the largest non-profit provider (DCI).
Is this the rationale?
As DaVita has discovered, the medical junk-bond business model that has been so profitable in American dialysis care does not succeed in other medical fields where patients are well and empowered. Installing business people in middle management positions in healthcare — as junk-bond financed companies must do — leads to perverse emphases on metrics, often achieved by any means possible. Junk-bond medicine will finanically succeed only with very vulnerable populations such as dialysis care, nursing home care, and hospice care.
Failing to provide information that allows comparisons of for-profit and non-profit dialysis providers greatly endangers patients and allows iatrogenic practices to continue unchecked for years.